Locations
Seattle, WA, USA · University of Washington, Seattle, WA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Other
founded in
2009
Immusoft is a biotechnology company that leads in developing B cells as biofactories for therapeutic protein delivery. Their innovative approach, Immune System Programming (ISP™), involves programming a patient's B cells to produce personalized protein therapeutics. This technology allows for the expansion of these programmed B cells into plasma cells that can manufacture therapeutic proteins for extended periods. Immusoft's focus on rare diseases positions it uniquely in the biotechnology market, with promising early data from clinical trials indicating significant potential for their lead candidate, ISP-001, in treating Mucopolysaccharidosis type I (MPS I).
Something looks off?